End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3.15 CNY | +3.62% |
|
+2.61% | -25.71% |
Mar. 29 | Tianjin Chase Sun Pharmaceutical Co.,Ltd Proposes Final Dividend for 2023 | CI |
Mar. 01 | Tianjin Chase Sun Pharmaceutical's 2023 Profit Slides 15% on Weak Revenue | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The company appears to be poorly valued given its net asset value.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-25.71% | 1.26B | C- | ||
+27.19% | 5.36B | B- | ||
-33.59% | 3.4B | C+ | ||
-2.97% | 2.9B | C | ||
-24.21% | 2.53B | B- | ||
-10.11% | 2.27B | - | D+ | |
+43.66% | 1.84B | - | ||
+46.15% | 1.42B | - | ||
+41.90% | 1.38B | - | ||
-13.92% | 1.37B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300026 Stock
- Ratings Tianjin Chase Sun Pharmaceutical Co.,Ltd